Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Rhea-AI Summary

Cognition Therapeutics (NASDAQ: CGTX) has released a new episode of its "Conversations" video podcast titled "Executing Clinical Research in Dementia with Lewy Bodies (DLB)" during DLB Awareness Month. The episode features a panel of experts discussing:

• Similarities and differences between DLB and Alzheimer's disease
• Unique symptoms experienced by DLB patients
• Design of the SHIMMER study of CT1812 in mild-to-moderate DLB
• Importance of identifying clinical and functional benefit signals in DLB, which currently lacks approved disease-modifying therapies

The podcast is moderated by Cognition's CMO, Dr. Anthony Caggiano, and includes three leading experts in the field. It is available on the Cognition website under the Conversations tab, presented in three chapters covering comparisons between Alzheimer's and DLB, SHIMMER study design, and metrics for success in signal-finding studies.

Positive

• Cognition Therapeutics is conducting the SHIMMER study of CT1812 in mild-to-moderate DLB
• The company is actively engaging with leading experts in the field of DLB research
• Cognition is raising awareness about DLB through educational content during DLB Awareness Month

Negative

• There are currently no approved disease-modifying therapies for DLB

PURCHASE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has released a new Conversations video podcast episode. The new episode, which has been launched during DLB Awareness Month, is titled “Executing Clinical Research in Dementia with Lewy Bodies (DLB).”

This conversation features a panel of experts who discuss the similarities and differences between DLB and Alzheimer’s disease, as well as the unique constellation of symptoms experienced by DLB patients. Panelists also discuss the design of the SHIMMER study of CT1812 in mild-to-moderate DLB, and the value of identifying signals of clinical and functional benefit in a condition for which there are currently no approved disease-modifying therapies.

Anthony Caggiano, M.D., Ph.D. CMO and head of R&D for Cognition Therapeutics moderates the discussion with three leading experts:

• James E. Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine;
• Lawrence S. Honig, MD, PhD, FAAN, professor of neurology at Columbia University Irving Medical Center; and
• David Shprecher, D.O., movement disorder director at Banner Sun Health Research Institute and a clinical associate professor at the University of Arizona.
  

Listen to episode nine, “Executing Clinical Research in Dementia with Lewy Bodies (DLB)” on the Conversations tab of the Cognition website. This conversation is presented in 3 Chapters: 1) Comparing Alzheimer’s disease and DLB; 2) SHIMMER Design and Outcomes; and 3) Metrics for Success in a Signal-finding Study.

Health Care Disclaimer
Our podcast series does not constitute the practice of medical advice, diagnosis or treatment. Always talk to your health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately.

About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We currently are investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these degenerative diseases, with an approach that is functionally distinct from other treatments. More about Cognition Therapeutics and our pipeline can be found at https://cogrx.com.

About the SHIMMER Study
The SHIMMER study (NCT05225415) is a double-blind, placebo-controlled Phase 2 clinical trial that enrolled 130 adults with mild-to-moderate DLB. Participants were evenly randomized to receive either placebo or one of two oral once-daily doses of CT1812 (100 mg or 300 mg) for six months. Participants are assessed throughout the study using the Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE), which track cognitive performance; the Clinician Assessment of Fluctuation (CAF) to measure the frequency and duration of cognitive fluctuations; and the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, an objective assessment of parkinsonism.

The SHIMMER study is supported by a grant award from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately $30 million and is being conducted in collaboration with James E. Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and the Lewy Body Dementia Association (LBDA). The SHIMMER study is being conducted at over 30 sites in the United States, many of which are LBDA centers of excellence.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including CT1812, and any expected or implied benefits or results, including that initial clinical results observed with respect to CT1812 will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of CT1812 and any analyses of the results therefrom, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact Information: Cognition Therapeutics, Inc. info@cogrx.com	Casey McDonald (media)  Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com	Mike Moyer (investors) LifeSci Advisors  mmoyer@lifesciadvisors.com

This press release was published by a CLEAR® Verified individual.

FAQ

What is the SHIMMER study by Cognition Therapeutics (CGTX) investigating?

The SHIMMER study is investigating CT1812, Cognition Therapeutics' drug candidate, for the treatment of mild-to-moderate Dementia with Lewy Bodies (DLB).

What experts are featured in Cognition Therapeutics' (CGTX) new podcast episode on DLB research?

The podcast features Dr. James E. Galvin from the University of Miami, Dr. Lawrence S. Honig from Columbia University, and Dr. David Shprecher from Banner Sun Health Research Institute and the University of Arizona.

What are the main topics discussed in Cognition Therapeutics' (CGTX) podcast on DLB research?

The podcast discusses comparisons between Alzheimer's disease and DLB, the design of the SHIMMER study, and metrics for success in signal-finding studies for DLB treatments.

When was the new episode of Cognition Therapeutics' (CGTX) podcast on DLB research released?

The new episode was released on October 22, 2024, during DLB Awareness Month.